Snapshot Profiling of the Antileishmanial Potency of Lead Compounds and Drug Candidates against Intracellular Leishmania donovani Amastigotes, with a Focus on Human-Derived Host Cells

ABSTRACT This study characterized the in vitro potencies of antileishmanial agents against intracellular Leishmania donovani amastigotes in primary human macrophages, obtained with or without CD14-positive monocyte enrichment, phorbol 12-myristate 13-acetate (PMA)-differentiated THP-1 cells, and mouse peritoneal exudate macrophages (PEMs). Host cell-dependent potency was confirmed for pentavalent and trivalent antimony. Fexinidazole was inactive against intracellular amastigotes across the host cell panel. Fexinidazole sulfone, (R)-PA-824, (S)-PA-824, and VL-2098 displayed similar potency in all of the host cells tested.

[1]  V. Yardley,et al.  A Replicative In Vitro Assay for Drug Discovery against Leishmania donovani , 2016, Antimicrobial Agents and Chemotherapy.

[2]  T. Dorlo,et al.  Functional Validation of ABCA3 as a Miltefosine Transporter in Human Macrophages , 2016, The Journal of Biological Chemistry.

[3]  A. Descoteaux,et al.  Leishmania survival in the macrophage: where the ends justify the means. , 2015, Current opinion in microbiology.

[4]  V. Yardley,et al.  Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis. , 2015, The Journal of antimicrobial chemotherapy.

[5]  N. Saravia,et al.  Leishmania panamensis infection and antimonial drugs modulate expression of macrophage drug transporters and metabolizing enzymes: impact on intracellular parasite survival. , 2014, The Journal of antimicrobial chemotherapy.

[6]  S. Norval,et al.  The R Enantiomer of the Antitubercular Drug PA-824 as a Potential Oral Treatment for Visceral Leishmaniasis , 2013, Antimicrobial Agents and Chemotherapy.

[7]  S. Cameron,et al.  Comparison of a High-Throughput High-Content Intracellular Leishmania donovani Assay with an Axenic Amastigote Assay , 2013, Antimicrobial Agents and Chemotherapy.

[8]  S. Shorte,et al.  High Content Analysis of Primary Macrophages Hosting Proliferating Leishmania Amastigotes: Application to Anti-leishmanial Drug Discovery , 2013, PLoS neglected tropical diseases.

[9]  C. Giulivi,et al.  Oxygen Tension Modulates Differentiation and Primary Macrophage Functions in the Human Monocytic THP-1 Cell Line , 2013, PloS one.

[10]  S. Sundar,et al.  Antimony-resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1 , 2013, Proceedings of the National Academy of Sciences.

[11]  A. Genovesio,et al.  An Image-Based High-Content Screening Assay for Compounds Targeting Intracellular Leishmania donovani Amastigotes in Human Macrophages , 2012, PLoS neglected tropical diseases.

[12]  J. Cano,et al.  Leishmaniasis Worldwide and Global Estimates of Its Incidence , 2012, PloS one.

[13]  K. Faber,et al.  Impact of Human Granulocyte and Monocyte Isolation Procedures on Functional Studies , 2012, Clinical and Vaccine Immunology.

[14]  S. Norval,et al.  The Anti-Trypanosome Drug Fexinidazole Shows Potential for Treating Visceral Leishmaniasis , 2012, Science Translational Medicine.

[15]  C. Nathan,et al.  In vitro differentiation of human macrophages with enhanced antimycobacterial activity. , 2011, The Journal of clinical investigation.

[16]  S. Croft,et al.  Leishmaniasis chemotherapy--challenges and opportunities. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[17]  K. Seifert.  Structures, Targets and Recent Approaches in Anti-Leishmanial Drug Discovery and Development , 2011, The open medicinal chemistry journal.

[18]  S. Sundar,et al.  Drug Resistance in Leishmaniasis , 2010, Journal of global infectious diseases.

[19]  S. Croft,et al.  In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent. , 2010, The Journal of antimicrobial chemotherapy.

[20]  Marc Daigneault,et al.  The Identification of Markers of Macrophage Differentiation in PMA-Stimulated THP-1 Cells and Monocyte-Derived Macrophages , 2010, PloS one.

[21]  M. Ouellette,et al.  Modulation of Gene Expression in Human Macrophages Treated with the Anti-Leishmania Pentavalent Antimonial Drug Sodium Stibogluconate , 2007, Antimicrobial Agents and Chemotherapy.

[22]  S. K. Choudhuri,et al.  Inhibition of ABC Transporters Abolishes Antimony Resistance in Leishmania Infection , 2007, Antimicrobial Agents and Chemotherapy.

[23]  R. Peeling,et al.  Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? , 2007, Nature Reviews Microbiology.

[24]  M. Matsumoto,et al.  Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles. , 2006, Journal of medicinal chemistry.

[25]  S. K. Choudhuri,et al.  Sodium Antimony Gluconate Induces Generation of Reactive Oxygen Species and Nitric Oxide via Phosphoinositide 3-Kinase and Mitogen-Activated Protein Kinase Activation in Leishmania donovani-Infected Macrophages , 2006, Antimicrobial Agents and Chemotherapy.

[26]  C. Shaha,et al.  Antimonial-induced Increase in Intracellular Ca2+ through Non-selective Cation Channels in the Host and the Parasite Is Responsible for Apoptosis of Intracellular Leishmania donovani Amastigotes* , 2003, Journal of Biological Chemistry.

[27]  B. Vion,et al.  Cutaneous leishmaniasis , 1990 .

[28]  S. Croft,et al.  An in-vitro system for determining the activity of compounds against the intracellular amastigote form of Leishmania donovani. , 1984, The Journal of antimicrobial chemotherapy.